ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,167 Cr (+13.9% YoY) and net profit of ₹101 Cr (+56.1% YoY) for Q1 FY27.
Akums reported FY26 revenue of ₹4,359 Cr (up 5.8%) and adjusted EBITDA of ₹522 Cr (up 13.3%). Strategy focuses on international CDMO expansion and margin improvement in API/Generic segments.
Akums delivered a resilient FY26 with 5.8% revenue growth, navigating high raw material inflation and soft domestic demand through double-digit volume growth in its core CDMO segment.
Akums delivered strong FY26 performance with 7.6% income growth and 14.5% EBITDA margins, driven by CDMO volume momentum despite API price erosion.
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,158 Cr (+9.7% YoY) and net profit of ₹81.3 Cr (-45.7% YoY) for Q4 FY26.